Serial KL-6 measurements in COVID-19 patients
Tóm tắt
SARS-CoV2-induced direct cytopathic effects against type II pneumocytes are suspected to play a role in mediating and perpetuating lung damage. The aim of this study was to evaluate serum KL-6 behavior in COVID-19 patients to investigate its potential role in predicting clinical course. Sixty patients (median age IQR, 65 (52–69), 43 males), hospitalized for COVID-19 at Siena COVID Unit University Hospital, were prospectively enrolled. Twenty-six patients were selected (median age IQR, 63 (55–71), 16 males); all of them underwent follow-up evaluations, including clinical, radiological, functional, and serum KL-6 assessments, after 6 (t1) and 9 (t2) months from hospital discharge. At t0, KL-6 concentrations were significantly higher than those at t1 (760 (311–1218) vs. 309 (210–408) p = 0.0208) and t2 (760 (311–1218) vs 324 (279–458), p = 0.0365). At t0, KL-6 concentrations were increased in patients with fibrotic lung alterations than in non-fibrotic group (755 (370–1023) vs. 305 (225–608), p = 0.0225). Area under the receiver operating curve (AUROC) analysis showed that basal KL-6 levels showed good accuracy in discriminating patients with fibrotic sequelae radiologically documented (AUC 85%, p = 0.0404). KL-6 concentrations in patients with fibrotic involvement were significantly reduced at t1 (755 (370–1023) vs. 290 (197–521), p = 0.0366) and t2 (755 (370–1023) vs. 318 (173–435), p = 0.0490). Serum concentrations of KL-6 in hospitalized COVID-19 patients may contribute to identify severe patients requiring mechanical ventilation and to predict those who will develop pulmonary fibrotic sequelae in the follow-up.
Tài liệu tham khảo
d’Alessandro M, Bergantini L, Cameli P, Vietri L, Lanzarone N, Alonzi V et al (2020) Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomark Med 68(6):414–421
Lanzarone N, Gentili F, Alonzi V, Bergantini L, d’Alessandro M, Rottoli P, et al. Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features. Intern Emerg Med. 2020.
d’Alessandro M, Bergantini L, Cameli P, Lanzarone N, Antonietta Mazzei M, Alonzi V et al (2020) Serum KL-6 levels in pulmonary Langerhans’ cell histiocytosis. Eur J Clin Invest 20:e13242
Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M et al (2017) Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 55(1):16–23
Bergantini L, Bargagli E, Cameli P, Cekorja B, Lanzarone N, Pianigiani L et al (2019) Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib. Respir Investig 57(3):290–291
Awano N, Inomata M, Kuse N, Tone M, Takada K, Muto Y et al (2020) Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019. Respir Investig 58(6):440–447
Xue M, Zheng P, Bian X, Huang Z, Huang H, Zeng Y et al (2020) Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China. Biosci Trends 14(4):290–296
d’Alessandro M, Cameli P, Bergantini L, Franchi F, Scolletta S, Bargagli E. Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes. J Med Virol. 2020.
d’Alessandro M, Cameli P, Refini RM, Bergantini L, Alonzi V, Lanzarone N et al (2020) Serum KL-6 concentrations as a novel biomarker of severe COVID-19. J Med Virol 92(10):2216–2220
D’alessandro M, Bennett D, Montagnani F, Cameli P, Perrone A, Bergantini L et al (2020) Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series. Minerva Med. https://doi.org/10.23736/S0026-4806.20.06638-0
Sato H, Callister MEJ, Mumby S, Quinlan GJ, Welsh KI, duBois RM et al (2004) KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J 23(1):142–145
Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F et al (2009) Clinical utility of serum beta-d-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med Tokyo Jpn 48(4):195–202
Arai Y, Obinata K, Sato Y, Hisata K, Tadokoro R, Tawa T et al (2001) Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia. Eur J Pediatr 160(7):425–429
Kawasaki Y, Aoyagi Y, Abe Y, Go H, Imamura T, Kaneko M et al (2009) Serum KL-6 levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis. J Med Virol 81(12):2104–2108
d’Alessandro M, Carleo A, Cameli P, Bergantini L, Perrone A, Vietri L et al (2020) BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases. Clin Exp Med 20(2):207–216
d’Alessandro M, Perillo F, Metella Refini R, Bergantini L, Bellisai F, Selvi E et al (2020) Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. Int Immunopharmacol 86:106748
Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K et al (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165(3):378–381
Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK et al (2017) Recommendations for a standardized pulmonary function report an official American thoracic society technical statement. Am J Respir Crit Care Med. 196(11):1463–1472
Zhu C, Zhao YB, Kong LF, Li ZH, Kang J (2016) The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases. Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis 39(2):93–97